RecruitingPhase 2NCT04920149
Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome
Studying Lynch syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ann-Sofie Backman
- Principal Investigator
- Ann-Sofie Backman, MD PhDKarolinska Institutet
- Intervention
- Mesalamine(drug)
- Enrollment
- 150 enrolled
- Eligibility
- 30 years · All sexes
- Timeline
- 2022 – 2045
Study locations (8)
- Aalborg University Hospital, Aalborg, Denmark
- Hvidovre Hospital, Hvidovre, Denmark
- Sahlgrenska University Hsospital, Gothenburg, Gothenburg, Sweden
- Skåne University Hospital, Malmo, Skåne County, Sweden
- Ersta Hospital/Ersta Diakoni, Stockholm, Sweden
- Karolinska University Hospital, Stockholm, Sweden
- Norrland University Hospital, Umeå, Sweden
- Akademiska hospital, Uppsala, Sweden
Collaborators
The Swedish Research Council · Karolinska Institutet
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04920149 on ClinicalTrials.govOther trials for Lynch syndrome
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNANCT06654128The Yield of Artificial Intelligence (GI Genius) in Lynch Syndrome - A Randomized Tandem-colonoscopy TrialSheba Medical Center
- RECRUITINGNCT06582914Lynch Syndrome Integrative Epidemiology and GeneticsUniversity of Colorado, Denver
- RECRUITINGNCT06447961PSYLIVED: the Psychological Impacts of Living With an Inherited Colorectal Cancer Predisposition SyndromeLondon North West Healthcare NHS Trust
- RECRUITINGNANCT05704010Videocapsule Endoscopy in Lynch SyndromeSan Raffaele University
- RECRUITINGNCT03303833The GEOLynch Cohort StudyWageningen University